ABOS NASDAQ
Acumen Pharmaceuticals, Inc.
1W: +11.9%
1M: -1.7%
3M: +7.1%
YTD: +11.9%
1Y: +2.3%
3Y: -34.7%
5Y: -83.7%
$2.26
-0.01 (-0.44%)
Weekly Expected Move ±11.7%
$2
$2
$2
$2
$2
Credit Risk of going bust: higher than 79% of companies Debt: 13.8% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the third-riskiest tenth, about 1 in 140 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.09 (down 96%), Acumen Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $26.3M against a stock market value of $163.4M.
Distance to default 2.66 (Merton model): prices to 2026-10-27, balance sheet 2026-09-30, debt counted $23.3M (short-term plus half of long-term), stock volatility 79.8%; Altman Z'' -24.06. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.09 (down 96%), Acumen Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $26.3M against a stock market value of $163.4M.
Distance to default 2.66 (Merton model): prices to 2026-10-27, balance sheet 2026-09-30, debt counted $23.3M (short-term plus half of long-term), stock volatility 79.8%; Altman Z'' -24.06. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
4 relationships4
As Filer
counterparties named
0
As Counterparty
mentioned by others
1
Rel. Types
2023-04-27
Earliest Filing
2025-07-15
Latest Filing
partner: 4
Counterparties (Filed by ABOS)
4 relationshipsCompanies named in ABOS's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| JCR Pharmaceuticals | — | partner | Strategic collaboration, option and license agreement to develop an Enhanced Brain Delivery product for Alzheimer's dise | 2025-07-15 | View |
| Halozyme, Inc. | HALO | partner | Acumen Pharmaceuticals entered into a non-exclusive collaboration and license agreement for ENHANZE technology and API s | 2023-11-09 | View |
| Stifel, Nicolaus & Company, Incorporated | — | partner | Sales Agent for at-the-market stock offerings | 2023-04-27 | View |
| BTIG, LLC | — | partner | Additional Sales Agent for at-the-market stock offerings | 2023-04-27 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-26 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-09-16 | Regulation FD; Exhibits | View | |
| 2026-08-12 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-06-16 | Regulation FD; Other Events; Exhibits | View | |
| 2026-06-03 | Shareholder Vote | View | |
| 2026-05-12 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-03-26 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-03-16 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Regulation FD Dis | Agreement | View |
| 2026-01-12 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-11-12 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-11-10 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2025-08-12 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-07-15 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibit | Agreement | View |
| 2025-06-05 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-13 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-03-27 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2024-11-12 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2024-08-13 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2024-05-14 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2024-03-26 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR